Revitus
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Revitus
Deals Shaping the Medical Industry (11/07)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
BioVascular Inc.
BioVascular is a beneficiary of Merck KGAA's incubator program. launched to encourage start-up companies to develop Merck's shelved technologies. BioVascular gained rights to saratin, a protein originally isolated from leech saliva. Saratin's ability to reduce platelet adhesion and the complications that can arise from it give it a number of potential applications, but BioVascular's initial focus is on vascular surgery, specifically the prevention of intimal hyperplasia that leads to graft failure.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice